BioTissue Technologies AG
BioTissue AG english
Breakthrough in developing autologous bones
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
Breakthrough in developing autologous bones/World innovation: BioSeed-Oral Bone
emphasizes our trail-blazing position in the tissue engineering market
(manufacture of living tissue replacement products)/Milestone in tissue
engineering offers immense future and growth potential/Launch in November 2001
Freiburg, Nov. 22, 2001 -BioTissue Technologies AG (SIN 618061), the pioneer in
the production of autologous tissue substitutes, has reached another milestone
in its history. For the first time, a research team at BioTissue Technologies
AG, the Freiburg University Medical Center and Berlin’s Charite Hospital have
succeeded in creating living cultures from periosteum samples from patients and
successfully implanting this in the upper jaw of the first patients. With this
mature serial production technology, BioTissue has a unique world patent to grow
bones.
The major advantage of this method of treatment with the BioSeed-Oral Bone
autologous bone replacement product stems from the fact that the body’s own bone
tissue is used so that there is no rejection of the implant. For BioTissue
Technologies AG, the new product opens up any manner of future opportunities.
The technology could be used to grow additional types of cartilage or bone – or
even blood vessels, nerves, muscles or, in the long-term, complete organs.
“With the BioSeed-Oral Bone world innovation now entering the controlled ap-
plications phase, BioTissue Technologies AG is expanding its position in skin
replacement products to include expertise in bone replacements,” explains Dr.
Wilhelm Brandner, CEO of BioTissue Technologies AG. “In this way, we are again
demonstrating that we are leading innovators in the market for tissue
engineering – and securing the company great growth potential in the long-term.”
BioTissue Technologies AG specializes in manufacturing tissue-engineering
products from autologous (the patient’s own) cells. At present, Bio-Tissue books
sales with its skin replacement products BioSeed-S and MelanoSeed as well as
with its oral mucosa replacement BioSeed-M.
The BioSeed-Oral Bone replacement product is the fruit of intensive technology
and know-how transfer between BioTissue Technologies AG and Dr. Michael
Sittinger at the Charite in Berlin, who developed the technology, as well as
Prof. Rainer Schmelzeisen, Director of the Mouth, Jaw and Facial Surgery Unit at
the Freiburg University Medical Center, and first user of BioSeed-Oral Bone.
Technology
Autologous bone tissue cells are removed from the patient’s jaw and grown by
means of cell cultures in the patient’s own blood serum. Sittinger explains just
how unique this technology is: “For the very first time we have succeeded in
combining autologous cells and a special scaffold – to grow a 3D tissue.” The
fact that it is based on the patient’s own cells ensures the recipient’s body
does not reject the BioSeed-Oral Bone on implantation. Dr. Eszter Tanczos, CSO
of BioTissue Technologies AG, adds: “BioSeed-Oral Bone is manufactured in our
labs that are certified in line with Good Manufacturing Practices and take only
about five weeks.”
Application:
For the first time, the new BioSeed-Oral Bone treatment method has been
successfully applied by the Director of the Mouth, Jaw and Facial Surgery Unit
at the Freiburg University Medical Center, Prof. Dr. Dr. Rainer Schmelzeisen.
“The bone cell patch specially grown for the patient is inserted into the
patient’s remaining bone substance. In this way, autologous bone matter is
available without it being extracted painfully from another point in his body
with the specific complications this entails,” explains Schmelzeisen. Bone
matter strengthened by means of BioSeed-Oral Bone can be used to firmly anchor
tooth roots. “The method of treatment, namely both the removal of periosteum and
the implantation of the bone replacement cultured, spares the patient far more
and involves far less risk than prior methods. Both processes can be conducted
on an out-patient basis,” Schmelzeisen continues.
“With this mature technology ready for the market, we are expanding the range of
tissue engineering applications not only in a trail-blazing step but at the
same time locking into countless other possible applications, too” Tanczos
concludes.
Should you have further questions, please contact:
BioTissue Technologies AG, Engesserstrasse 4a/4b, 79108 Freiburg, Germany
Martin Braendle, Investor- and Public Relations Manager
Tel. +49-761-7676-110
Fax +49-761-7676-155
martin.braendle@biotissue-tec.com
http://www.biotissue-tec.com
end of message, (c)DGAP 22.11.2001
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found